fluvoxamine

Summary

Summary: A selective serotonin reuptake inhibitor. It is effective in the treatment of depression, obsessive-compulsive disorders, anxiety, panic disorders, and alcohol amnestic disorders.

Top Publications

  1. ncbi Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study
    R Zanardi
    Istituto Scientifico Ospedale San Raffaele, Department of Neuropsychiatric Sciences, School of Medicine, University of Milan, Italy
    J Clin Psychopharmacol 18:441-6. 1998
  2. ncbi Pharmacokinetics of selective serotonin reuptake inhibitors
    C Hiemke
    Department of Psychiatry, University of Mainz, Germany
    Pharmacol Ther 85:11-28. 2000
  3. ncbi Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine
    Guido Stirnimann
    Institute of Clinical Pharmacology and Visceral Research, University of Bern, Bern, Switzerland
    Europace 12:282-3. 2010
  4. ncbi A pilot placebo-controlled study of fluvoxamine for pathological gambling
    Carlos Blanco
    Department of Psychiatry, Columbia University, New York, New York, USA
    Ann Clin Psychiatry 14:9-15. 2002
  5. ncbi Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level
    S Benmansour
    Department of Pharmacology, University of Texas Health Science Center, San Antonio, Texas 78284, USA
    J Neurosci 19:10494-501. 1999
  6. ncbi Sigma-1 receptor stimulation with fluvoxamine activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding
    Md Shenuarin Bhuiyan
    Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
    Eur J Pharmacol 650:621-8. 2011
  7. ncbi Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates
    M Olga Rojas-Corrales
    Pharmacology and Neuroscience Research Group, Department of Neuroscience, Faculty of Medicine, University of Cadiz, Cadiz, Spain
    J Psychopharmacol 18:404-11. 2004
  8. pmc Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status
    Tsukasa Uno
    Department of Clinical Pharmacology, Hirosaki University School of Medicine, Japan
    Br J Clin Pharmacol 61:309-14. 2006
  9. ncbi Effects of repeated milnacipran and fluvoxamine treatment on mechanical allodynia in a mouse paclitaxel-induced neuropathic pain model
    Soh Katsuyama
    Department of Clinical Pharmaceutics, Tohoku Pharmaceutical University, 4 4 1 Komatsushima, Aoba ku, Sendai 981 8558, Japan
    Biomed Res 34:105-11. 2013
  10. ncbi Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine
    Jun Fujishiro
    Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, 760 Morooka cho, Kohoku, Yokohama 222 8567, Japan
    Eur J Pharmacol 454:183-8. 2002

Detail Information

Publications238 found, 100 shown here

  1. ncbi Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study
    R Zanardi
    Istituto Scientifico Ospedale San Raffaele, Department of Neuropsychiatric Sciences, School of Medicine, University of Milan, Italy
    J Clin Psychopharmacol 18:441-6. 1998
    ..study was undertaken to investigate whether the addition of pindolol could improve the therapeutic response to fluvoxamine of depressed patients with psychotic features...
  2. ncbi Pharmacokinetics of selective serotonin reuptake inhibitors
    C Hiemke
    Department of Psychiatry, University of Mainz, Germany
    Pharmacol Ther 85:11-28. 2000
    The five selective serotonin reuptake inhibitors (SSRIs), fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, have similar antidepressant efficacy and a similar side effect profile...
  3. ncbi Brugada syndrome ECG provoked by the selective serotonin reuptake inhibitor fluvoxamine
    Guido Stirnimann
    Institute of Clinical Pharmacology and Visceral Research, University of Bern, Bern, Switzerland
    Europace 12:282-3. 2010
    ..to a non-expression of the mutant allele, was prescribed the selective serotonin reuptake inhibitor (SSRI) fluvoxamine (Floxyfral), 100 mg per day. His normal baseline ECG changed to a characteristic Brugada-Type-1-ECG pattern...
  4. ncbi A pilot placebo-controlled study of fluvoxamine for pathological gambling
    Carlos Blanco
    Department of Psychiatry, Columbia University, New York, New York, USA
    Ann Clin Psychiatry 14:9-15. 2002
    The objective of this study was to evaluate the efficacy of fluvoxamine in the treatment of pathological gambling. Thirty-two patients were treated for 6 months in a double-blind, placebo-controlled study of fluvoxamine 200 mg/day...
  5. ncbi Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level
    S Benmansour
    Department of Pharmacology, University of Texas Health Science Center, San Antonio, Texas 78284, USA
    J Neurosci 19:10494-501. 1999
    ..High-speed in vivo electrochemical recordings were used to assess the ability of the SSRI fluvoxamine to modulate the clearance of locally applied serotonin in the CA3 region of hippocampus in drug- or vehicle-..
  6. ncbi Sigma-1 receptor stimulation with fluvoxamine activates Akt-eNOS signaling in the thoracic aorta of ovariectomized rats with abdominal aortic banding
    Md Shenuarin Bhuiyan
    Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
    Eur J Pharmacol 650:621-8. 2011
    In the present study, we investigated the vasculoprotective effect of sigma-1 receptor stimulation with fluvoxamine on pressure overload hypertrophy-induced vascular injury in the thoracic aorta and defined mechanisms underlying that ..
  7. ncbi Antidepressant-like effect of tramadol and its enantiomers in reserpinized mice: comparative study with desipramine, fluvoxamine, venlafaxine and opiates
    M Olga Rojas-Corrales
    Pharmacology and Neuroscience Research Group, Department of Neuroscience, Faculty of Medicine, University of Cadiz, Cadiz, Spain
    J Psychopharmacol 18:404-11. 2004
    ..Moreover, we compared the effects of tramadol and its enantiomers with those of antidepressants (desipramine, fluvoxamine and venlafaxine) and opiates [morphine (-)-methadone and levorphanol]...
  8. pmc Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status
    Tsukasa Uno
    Department of Clinical Pharmacology, Hirosaki University School of Medicine, Japan
    Br J Clin Pharmacol 61:309-14. 2006
    ..Our objective was to evaluate the possible effect of an inhibitor of CYP2C19, fluvoxamine, and compare the inhibitory effect of fluvoxamine on the metabolism of rabeprazole between CYP2C19 genotypes.
  9. ncbi Effects of repeated milnacipran and fluvoxamine treatment on mechanical allodynia in a mouse paclitaxel-induced neuropathic pain model
    Soh Katsuyama
    Department of Clinical Pharmaceutics, Tohoku Pharmaceutical University, 4 4 1 Komatsushima, Aoba ku, Sendai 981 8558, Japan
    Biomed Res 34:105-11. 2013
    ..Milnacipran, a serotonin/noradrenaline reuptake inhibitor and fluvoxamine, a selective serotonin reuptake inhibitor, have shown efficacy against several chronic pain syndromes...
  10. ncbi Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine
    Jun Fujishiro
    Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, 760 Morooka cho, Kohoku, Yokohama 222 8567, Japan
    Eur J Pharmacol 454:183-8. 2002
    ..spontaneous defecation and passive avoidance performance using mice and compared the results with those using fluvoxamine, another selective serotonin reuptake inhibitor, and clomipramine, a tricyclic antidepressant with serotonin ..
  11. ncbi A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response
    T Pearlstein
    Department of Psychiatry and Human Behavior, Women s Behavioral Health Program, Brown Medical School, 101 DudleyStreet, Providence, RI 02905, U S A
    Arch Womens Ment Health 6:147-51. 2003
    Twenty subjects with binge eating disorder were randomly assigned to flexible-dose fluvoxamine or placebo for 12 weeks...
  12. pmc Antiulcer activity of fluvoxamine in rats and its effect on oxidant and antioxidant parameters in stomach tissue
    Hakan Dursun
    Department of Pharmacology, Ataturk University, Faculty of Medicine, Erzurum, Turkey
    BMC Gastroenterol 9:36. 2009
    ..date, however, there is no information available regarding the antiulcer activity for a similar antidepressant, fluvoxamine. This study aimed to investigate the antiulcer effects of fluvoxamine and to determine its relationship with ..
  13. ncbi Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study
    Pinhas N Dannon
    Rehovot Community Mental Health and Rehabilitation Center Affililated to Ness Ziona Medical Center and Tel Aviv University, Rehovot, Israel
    Clin Neuropharmacol 28:6-10. 2005
    ..The aim of the study is to compare the effectiveness of topiramate versus fluvoxamine in the treatment of PG...
  14. pmc Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways
    Tomoko Nishimura
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan
    PLoS ONE 3:e2558. 2008
    ..However, their pharmacology is quite heterogeneous. The SSRI fluvoxamine, with sigma-1 receptor agonism, is shown to potentiate nerve-growth factor (NGF)-induced neurite outgrowth in ..
  15. pmc Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
    Norio Yasui-Furukori
    Department of Clinical Pharmacology, Hirosaki University, School of Medicine, Hirosaki, Japan
    Br J Clin Pharmacol 57:487-94. 2004
    Omeprazole is mainly metabolized by the polymorphic cytochrome P450 (CYP) 2C19. The inhibitory effect of fluvoxamine, an inhibitor of CYP2C19 as well as CYP1A2, on the metabolism of omeprazole was compared between different genotypes for ..
  16. ncbi Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered
    Ian Hindmarch
    University of Surrey, Guildford, UK
    Hum Psychopharmacol 25:193-200. 2010
    ..of the involvement of sigma-1 receptor agonism in the mechanism of action of some antidepressants, notably fluvoxamine. Sigma-1 receptors are abundant in areas affected by depression/stress-induced cerebral atrophy and their ..
  17. ncbi Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder
    Lorrin M Koran
    Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, CA 94305, USA
    Compr Psychiatry 51:373-9. 2010
    We hypothesized that subjects with obsessive-compulsive disorder (OCD) who received extended-release fluvoxamine (fluvoxamine ER) in a 12-week placebo-controlled trial would exhibit improvements in psychosocial domains of health-related ..
  18. ncbi Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism
    Masaki Kato
    Department of Neuropsychiatry, Kansai Medical University, Moriguchi, Osaka, Japan
    Int Clin Psychopharmacol 20:151-6. 2005
    ..Clinical responses to paroxetine and fluvoxamine were evaluated by total and cluster depressive symptoms for 81 Japanese patients who were diagnosed with major ..
  19. ncbi Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats
    Miki Yamauchi
    Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    Pharmacol Biochem Behav 78:683-9. 2004
    The effectiveness of fluvoxamine, a selective serotonin re-uptake inhibitor (SSRI), in the treatment of anxiety disorders, such as obsessive-compulsive, panic and social anxiety disorders, has been confirmed in clinical studies...
  20. ncbi Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial
    F Bogetto
    Service for Depressive and Anxiety Disorders, Department of Neuroscience, University of Turin, Via Cherasco 11, 10126, Turin, Italy
    Psychiatry Res 96:91-8. 2000
    ..The aim of this study was to investigate the efficacy and tolerability of olanzapine addition to fluvoxamine-refractory OCD patients and to assess if a comorbid chronic tic disorder or a concomitant schizotypal ..
  21. ncbi Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine
    V Ozdemir
    Department of Pharmacology, University of Toronto, Ontario, Canada
    J Clin Psychopharmacol 21:603-7. 2001
    ..In addition, we describe the effect of grapefruit juice or low-dose fluvoxamine (25-50 mg/d) coadministration on clozapine and active metabolite norclozapine steady-state plasma concentration ..
  22. ncbi No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment
    Hitoshi Takahashi
    Department of Psychiatry, Akita University School of Medicine, 1 1 1, Hondo, 010 8543, Akita, Japan
    Eur Neuropsychopharmacol 12:477-81. 2002
    ..the most frequent side-effect of selective serotonin reuptake inhibiters (SSRIs), in 66 patients treated with fluvoxamine in a protocolized-dosing method...
  23. ncbi Association study between vesicle-associated membrane protein 2 gene polymorphisms and fluvoxamine response in Japanese major depressive patients
    Shinichi Saito
    Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan
    Neuropsychobiology 54:226-30. 2006
    ..The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine.
  24. ncbi Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder
    A C Volkers
    Department of Psychiatry, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    Pharmacopsychiatry 37:18-25. 2004
    ..We studied the effects of two different types of antidepressant treatments (imipramine and fluvoxamine), in addition to the effect of depressive mood, on the cardiovascular system in depressed patients.
  25. ncbi Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys
    T Kakiuchi
    Central Research Laboratory, Hamamatsu Photonics K. K, Shizuoka, Japan
    Synapse 40:170-9. 2001
    ..When the SERT blocker fluvoxamine (1 mg/kg) was administered intravenously 30 min after tracer injection, specific binding of SERT was displaced ..
  26. pmc Tolerability and safety of fluvoxamine and other antidepressants
    H G M Westenberg
    Department of Psychiatry, University Medical Centre, Utrecht, The Netherlands
    Int J Clin Pract 60:482-91. 2006
    ..Although SSRIs (and venlafaxine) have similar adverse effects, certain differences are emerging. Fluvoxamine may have fewer effects on sexual dysfunction and sleep pattern...
  27. ncbi Fluvoxamine modulates pain sensation and affective processing of pain in human brain
    Hidenori Nemoto
    Department of Neurology and Clinical Research, Gunma University School of Medicine, Maebashi, Japan
    Neuroreport 14:791-7. 2003
    To better understand the antinociceptive effect of fluvoxamine, we measured regional cerebral blood flow during laser-evoked pain and hot sensations using H(2)15O positron emission tomography and also subjective pain and hot sensations ..
  28. ncbi Effects of chronic selective serotonin reuptake inhibitors on 8-OH-DPAT-induced facilitation of ejaculation in rats: comparison of fluvoxamine and paroxetine
    Trynke R de Jong
    Department of Anatomy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Psychopharmacology (Berl) 179:509-15. 2005
    ..The involvement of 5-HT1A receptors is likely, since 5-HT1A receptor agonists accelerate ejaculation and chronic SSRI treatment is thought to desensitize 5-HT1A receptors...
  29. ncbi Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors
    Giuseppe Maina
    Mood and Anxiety Disorders Unit, Department of Neuroscience, University of Turin, Torino, Italy
    J Clin Psychiatry 65:1365-71. 2004
    ..The aim of the present study was to assess changes in weight in obsessive-compulsive disorder (OCD) patients treated for 2.5 years with clomipramine or selective serotonin reuptake inhibitors...
  30. ncbi A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study
    Tomihisa Niitsu
    Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan
    J Clin Psychopharmacol 32:593-601. 2012
    ..were involved in cognitive impairments in patients with schizophrenia and that the sigma-1 receptor agonist fluvoxamine was effective in treating cognitive impairments in animal models of schizophrenia and in some patients with ..
  31. pmc Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine
    Sang Keun Chung
    Department of Psychiatry, Chonbuk National University Medical School, Jeonju, Korea
    Yonsei Med J 50:441-4. 2009
    ..We present a case of a 36-year-old pathological gambler who was treated with fluvoxamine, a selective serotonin reuptake inhibitor, and who was assessed by functional MRI before and after drug ..
  32. pmc Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics
    Kerry E Culm-Merdek
    Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts New England Medical Center, 136 Harrison Avenue, Boston, MA 02111, USA
    Br J Clin Pharmacol 60:486-93. 2005
    Coadministration of fluvoxamine impairs the clearance of caffeine and prolongs its elimination half-life, which is attributable to inhibition of CYP1A2 by fluvoxamine. The clinical importance of this interaction is not established.
  33. ncbi Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes
    Norio Yasui-Furukori
    Department of Clinical Pharmacology, Hirosaki University, School of Medicine, Hirosaki 036 8562, Japan
    J Clin Pharmacol 44:1223-9. 2004
    ..Lansoprazole is a substrate of CYP2C19 and CYP3A4. The aim of this study was to compare the inhibitory effects of fluvoxamine, an inhibitor of CYP2C19, on the metabolism of lansoprazole between CYP2C19 genotypes...
  34. ncbi Gestational exposure to the organophosphate chlorpyrifos alters social-emotional behaviour and impairs responsiveness to the serotonin transporter inhibitor fluvoxamine in mice
    Aldina Venerosi
    Section of Neurotoxicology and Neuroendocrinology, Department of Cell Biology and Neurosciences, Istituto Superiore di Sanita, V le Regina Elena 299, Rome, Italy
    Psychopharmacology (Berl) 208:99-107. 2010
    ..Studies from animal models indicate that CPF exposure during development at low doses can target different neurotransmitter systems in the absence of overt cholinergic effects...
  35. ncbi Patterns of c-fos expression induced by fluvoxamine are different after acute vs. chronic oral administration
    J G Veening
    Dept of Anatomy and Embryology, Fac of Medical Sciences, University of Nijmegen, Netherlands
    Eur Neuropsychopharmacol 8:213-26. 1998
    b>Fluvoxamine is a selective serotonin (5-HT) reuptake inhibitor (SSRI) with a broad spectrum of behavioral and therapeutic effects, e.g. in depressive illness...
  36. ncbi Co-administration of ramelton and fluvoxamine to increase levels of interleukin-2
    Richard E Kast
    Department of Psychiatry, University of Vermont, 2 Church Street, Burlington, VT 05401, United States
    Med Hypotheses 67:1389-90. 2006
    ..This liver metabolism is mediated by the CYP1A2 enzyme. It turns out that the medication fluvoxamine approved by the FDA for the treatment of obsessive compulsive disorder is a potent inhibitor of the CYP1A2 ..
  37. ncbi Fluvoxamine, a selective serotonin reuptake inhibitor, and 5-HT2C receptor inactivation induce appetite-suppressing effects in mice via 5-HT1B receptors
    Katsunori Nonogaki
    Center of Excellence, Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Japan
    Int J Neuropsychopharmacol 10:675-81. 2007
    ..Here, we report that fluvoxamine (3-30 mg/kg), a selective serotonin reuptake inhibitor (SSRI), in the presence of SB 242084 (1-2 mg/kg), a ..
  38. ncbi Neuroendocrine (HPA axis) and clinical correlates during fluvoxamine and amitriptyline treatment
    Eugenia Rota
    Department of Neuroscience, University of Turin, Via Cherasco 15, Turin 10126, Italy
    Psychiatry Res 133:281-4. 2005
    ..effect of amitriptyline on hypothalamic-pituitary-adrenocortical (HPA) axis activity was compared with that of fluvoxamine in 38 patients suffering from DMS-IV major depressive disorder...
  39. ncbi Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients
    J A Carrillo
    Department of Pharmacology and Psychiatry, Medical School, University of Extremadura, Badajoz, Spain
    J Clin Psychopharmacol 19:494-9. 1999
    This study investigated to what extent fluvoxamine affects the pharmacokinetics of thioridazine (THD) in schizophrenic patients under steady-state conditions...
  40. ncbi Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone (DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells
    Miho Nakano
    Department of Neuropsychiatry, St Marianna University School of Medicine, 2 16 1 Sugao Miyamae ku Kawasaki, Kanagawa 216 8511, Japan
    Life Sci 86:309-14. 2010
    ..Furthermore, the PLC-gamma/IP(3)/Ca(2+) pathway is regulated by the sigma-1 receptors. Here, we examined whether fluvoxamine (FLV) activated Akt-1 and increased phosphorylation of Akt-1 via sigma-1 receptor in PC12 cells.
  41. ncbi An open clinical trial of fluvoxamine treatment of psychogenic excoriation
    L M Arnold
    Biological Psychiatry Program, University of Cincinnati Medical Center, Ohio 45267 0559, USA
    J Clin Psychopharmacol 19:15-8. 1999
    The purpose of this study was to examine the safety and efficacy of fluvoxamine in the treatment of psychogenic (neurotic) skin excoriation...
  42. ncbi Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders
    D P Figgitt
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 60:925-54. 2000
    b>Fluvoxamine is a potent and selective serotonin reuptake inhibitor (SSRI) that has little or no effect on other monoamine reuptake mechanisms...
  43. ncbi Fluvoxamine treatment of major depression associated with multiple sclerosis
    Francesco Benedetti
    Department of Neuropsychiatric Sciences, Universita Vita Salute San Raffaele, School of Medicine, Milan, Italy
    J Neuropsychiatry Clin Neurosci 16:364-6. 2004
    b>Fluvoxamine 200 mg was administered for 3 months to a group of 43 interferon beta-1b treated patients affected by major depression associated with multiple sclerosis. Despite a 16.3% attrition rate, 79% of patients achieved response...
  44. ncbi Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study
    Sonja Ständer
    Department of Dermatology, Clinical Neurodermatology, University of Munster, Munster, Germany
    Acta Derm Venereol 89:45-51. 2009
    ..Paroxetine and fluvoxamine were tested in a total of 72 pruritic patients (27 men, 45 women, age range 28-88 years, mean age 59.2 years)...
  45. ncbi Serotonin syndrome induced by fluvoxamine and oxycodone
    Harindra Karunatilake
    The Canberra Hospital, Canberra, New South Wales, Australia
    Ann Pharmacother 40:155-7. 2006
    To report a case of severe serotonergic symptoms following the addition of oxycodone to fluvoxamine.
  46. ncbi Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine
    Rocco Orlando
    Department of Pharmacology and Anesthesiology, University of Padua, Italy
    Clin Pharmacol Ther 79:489-99. 2006
    In vivo inhibition of cytochrome P450 (CYP) 1A2 by fluvoxamine causes a reduction in the clearance of the high-extraction drug lidocaine, which decreases in proportion to the degree of liver dysfunction...
  47. ncbi Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism
    Yoko Sugie
    Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Japan
    J Autism Dev Disord 35:377-85. 2005
    We studied the correlation between response to fluvoxamine and serotonin transporter gene promoter region polymorphism (5-HTTLPR)...
  48. ncbi Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine
    Damiaan Denys
    Department of Psychiatry, The Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, P O Box 85500, 3508 GA Utrecht, The Netherlands
    Psychopharmacology (Berl) 176:195-203. 2004
    ....
  49. ncbi Fluvoxamine treatment of a child with severe PDD: a single case study
    C Kauffmann
    Department of Psychiatry and Behavioral Sciences, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA
    Psychiatry 64:268-77. 2001
    ..We report on a single case study of the use of fluvoxamine with a 7-year-old Caucasian girl with severe pervasive developmental disorder...
  50. ncbi Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial
    W Milano
    Department of Pharmaceutical Sciences, Mental Health Unit, University of Salerno, Naples, Italy
    Adv Ther 22:278-83. 2005
    ..We conducted a randomized controlled trial to verify the efficacy of the SSRI fluvoxamine in patients with a diagnosis of BN...
  51. ncbi Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19
    Caiping Yao
    Department of Pharmaceutics, University of Washington, Seattle, Washington 98195 7610, USA
    Drug Metab Dispos 31:565-71. 2003
    A previous study suggested that fluvoxamine inhibition potency toward CYP1A2 is 10 times greater in vivo than in vitro...
  52. ncbi Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels
    Reiji Yoshimura
    Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
    Psychiatry Clin Neurosci 60:389-93. 2006
    ..treatment of obsessive-compulsive disorder (OCD) in three patients with the addition of risperidone to ongoing fluvoxamine treatment...
  53. ncbi Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride
    M Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 69:194-200. 2001
    OBJECTIVE: Our objective was to study the effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride, a new sulfonylurea antidiabetic drug...
  54. ncbi Sigma1-receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in mice
    Hideaki Tagashira
    Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan
    Am J Physiol Heart Circ Physiol 299:H1535-45. 2010
    ..Here, we investigated the role of σ(1)-receptor (σ(1)R) stimulation with fluvoxamine on myocardial hypertrophy and cardiac functional recovery...
  55. ncbi Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine
    G Clerc
    , Pontorson, France
    Int Clin Psychopharmacol 16:145-51. 2001
    ..reuptake inhibitor, were compared with those of the selective serotonin reuptake inhibitor, fluvoxamine, in 113 patients with moderate to severe major depression. Treatment with milnacipran, 50 mg b.d...
  56. ncbi Intracerebroventricular fluvoxamine administration inhibited pain behavior but increased Fos expression in affective pain pathways
    Takayuki Hayashi
    Department of Physiology, Tokyo Women s Medical University, School of Medicine, 8 1 Kawada cho, Shinjuyuku ku, Tokyo 162 8666, Japan
    Pharmacol Biochem Behav 91:441-6. 2009
    Anti-nociceptive effects of fluvoxamine, administered by intracerebroventricular (i.c.v.) injection, include inhibited pain behavior in both formalin-induced acute pain (p<0.05-0.01) and sciatic nerve ligation-allodynia (p<0.03)...
  57. ncbi Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial
    J I Hudson
    Biological Psychiatry Laboratory, McLean Hospital, Belmont, MA 02178, USA
    Am J Psychiatry 155:1756-62. 1998
    The purpose of this study was to assess the efficacy of fluvoxamine in the treatment of binge-eating disorder...
  58. ncbi Effects of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats
    Akiyoshi Saitoh
    Department of Pathophysiology and Therapeutics, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 4 41, Ebara 2 Chome, Shinagawa ku, Tokyo, 142 8501, Japan
    Psychopharmacology (Berl) 191:857-65. 2007
    ..It has been reported that many of the behavioral and serotonergic neuronal changes observed in olfactory bulbectomy (OBX) were improved by subchronic administration of a variety of antidepressants...
  59. ncbi A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression
    T Otsubo
    Department of Psychiatry, Showa University School of Medicine, 1 5 8 Hatanodai, Shinagawa ku, Tokyo 142 8566, Japan
    Pharmacopsychiatry 38:30-5. 2005
    The aim of this study was to compare the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
  60. ncbi Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder
    Akiko Okuda
    Department of Psychiatry, Okehazama Hospital Fujita Mental Care Center, Aichi, Japan
    Psychiatry Clin Neurosci 64:268-73. 2010
    ..The aim of this study was to analyze the relation between treatment response and the duration of untreated illness (DUI) in 133 outpatients with the first major depressive disorder (MDD) episode...
  61. ncbi Effect of fluvoxamine on the pharmacokinetics of quinidine
    P Damkier
    Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense University
    Eur J Clin Pharmacol 55:451-6. 1999
    ..To investigate the possible involvement of cytochromes CYP1A2 and CYP2C19 in the in vivo oxidative metabolism of quinidine...
  62. ncbi Possible involvement of peripheral serotonin 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus
    Mina Fujiwara-Sawada
    Pharmaceutical Research Center, Meiji Seika Kaisha Ltd, 760 Morooka cho, Kohoku Ku, Yokohama 222 8567, Japan
    J Pharm Pharmacol 55:271-4. 2003
    Selective serotonin reuptake inhibitors fluvoxamine and fluoxetine, as well as serotonin (5-HT), induced vomiting in Suncus murinus (a house musk shrew)...
  63. ncbi CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects
    Koichi Ohara
    Clinical Research Institute, National Minami Hanamaki Hospital, Hanamaki, Japan
    Eur J Clin Pharmacol 58:659-61. 2003
    The purpose of the present study was to investigate whether plasma fluvoxamine (FV) concentration is associated with CYP2D6*10 allele polymorphisms.
  64. ncbi Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide
    Oliver von Richter
    Exploratory Medicine, ALTANA Pharma AG, Konstanz, Germany
    Clin Pharmacokinet 46:613-22. 2007
    To investigate the effects of steady-state dosing of fluvoxamine, an inhibitor of cytochrome P450 (CYP) 1A2 and CYP2C19, on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor and its ..
  65. ncbi Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial
    Hitoshi Takahashi
    Department of Neuropsychiatry, Akita University School of Medicine, 1 1 1 Hondo, Akita 010 8543, Japan
    Hum Psychopharmacol 17:95-8. 2002
    We investigated the efficacy and safety of augmenting risperidone with fluvoxamine for the treatment of residual positive and negative symptoms in patients with chronic schizophrenia who had shown an incomplete response to risperidone...
  66. ncbi Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia?
    Kenji Hashimoto
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1 8 1 Inohana, Chiba 260 8670, Japan
    CNS Neurol Disord Drug Targets 8:470-4. 2009
    ..Among all antidepressants, fluvoxamine was the most potent sigma-1 receptor agonist...
  67. ncbi A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine
    Eriko Nakatani
    Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Psychother Psychosom 74:269-76. 2005
    The aim of this study was to confirm and compare the efficacy of fluvoxamine (the only licensed SSRI for treatment for OCD in Japan) and behavior therapy in treating Japanese patients with OCD...
  68. ncbi Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice
    Yukio Ago
    Laboratory of Medicinal Pharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
    Eur J Pharmacol 520:86-90. 2005
    We have recently reported that coadministration of sulpiride, an antipsychotic drug, and fluvoxamine, a selective serotonin (5-HT) reuptake inhibitor, selectively increases in vivo dopamine release in the prefrontal cortex...
  69. ncbi Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors
    Motoko Honda
    Laboratory of CNS Pharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3 1 Tanabe dori, Mizuho ku, Nagoya 467 8603, Japan
    Neuropharmacology 51:866-72. 2006
    ..We examined the effects of fluvoxamine, a selective serotonin reuptake inhibitor, on mechanical allodynia and its mechanism of action in the mouse ..
  70. ncbi The light-enhanced startle paradigm as a putative animal model for anxiety: effects of chlordiazepoxide, flesinoxan and fluvoxamine
    Reinoud de Jongh
    Department of Psychopharmacology, Faculty of Pharmacy, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands
    Psychopharmacology (Berl) 159:176-80. 2002
    ..By placing a rat in a brightly lit environment, which is a naturally aversive stimulus to rats, the amplitude of the startle response to a startle-eliciting noise burst is increased...
  71. ncbi Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats
    Trynke R de Jong
    Department of Anatomy, Radboud University Nijmegen Medical Centre, Intern Mail Nr 230 Postbus 9101 6500 HB, Nijmegen, The Netherlands
    Eur Neuropsychopharmacol 16:39-48. 2006
    ..Male Wistar rats were treated with paroxetine (15 mg/kg p.o.) or fluvoxamine (30 mg/kg p.o.) throughout adolescence...
  72. ncbi Spectrophotometric study for the reaction between fluvoxamine and 1,2-naphthoquinone-4-sulphonate: Kinetic, mechanism and use for determination of fluvoxamine in its dosage forms
    Ibrahim A Darwish
    Department of Pharmaceutical Chemistry, King Saud University, Riyadh, Saudi Arabia
    Spectrochim Acta A Mol Biomol Spectrosc 72:897-902. 2009
    ..study was carried out, for the first time, to investigate the reaction between the antidepressant fluvoxamine (FXM) and 1,2-naphthoquinone-4-sulphonate (NQS) reagent...
  73. ncbi Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone
    Y W Francis Lam
    Department of Pharmacology, University of Texas Health Science Center at San Antonio, USA
    J Clin Pharmacol 43:1274-82. 2003
    ..study was to investigate pharmacokinetic and pharmacodynamic interactions between midazolam and fluoxetine, fluvoxamine, nefazodone, and ketoconazole...
  74. ncbi Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioned fear
    X B Li
    Department of Psychiatry, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita ku, Sapporo, 060 8638, Japan
    Eur J Pharmacol 425:43-50. 2001
    The present study investigated the acute effects of flesinoxan (a selective 5-HT(1A) receptor agonist), fluvoxamine (a selective serotonin reuptake inhibitor) and their co-administration on the expression of conditioned freezing, and ..
  75. ncbi Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder
    Jonathan Davidson
    Department of Psychiatry, Duke University Medical Center, Trent Drive, 4th Floor, Room 4082B, Durham, NC 27710, USA
    J Clin Psychopharmacol 24:118-25. 2004
    ..We report the results of a multicenter, randomized, placebo-controlled trial comparing the efficacy, safety, and tolerability of fluvoxamine controlled release (CR) to placebo in patients with generalized social anxiety disorder.
  76. ncbi Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population
    Taro Kishi
    Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
    Neuropsychobiology 59:234-8. 2009
    ..Therefore, we examined the association between the orphan nuclear receptor Rev-erbalpha gene (NR1D1) and the efficacy of fluvoxamine treatment in 118 Japanese patients with major depressive disorder.
  77. ncbi Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population
    Takenori Okumura
    Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan
    Neuropsychobiology 61:57-63. 2010
    ..Therefore, we studied the association of nNOS gene (NOS1) and mood disorders and the efficacy of fluvoxamine treatment in Japanese MDD patients.
  78. ncbi Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine
    Keizo Yoshida
    Department of Psychiatry, Akita University School of Medicine, Akita, Japan
    Neuropsychobiology 48:10-3. 2003
    ..in the promoter region of the 5-HT(2A) gene were associated with the incidence of nausea induced by fluvoxamine. Fluvoxamine was administered for 6 weeks with a specific dosage plan (50-200 mg/day) in 66 Japanese major ..
  79. ncbi Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients
    G M Asnis
    Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, 111 E 210th Street, Bronx, New York, NY 10467 2490, USA
    Psychiatry Res 103:1-14. 2001
    Serotonergic mechanisms have been implicated in panic disorder, and several preliminary studies suggest that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is helpful in its treatment...
  80. ncbi Association analysis of group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population
    Tomoko Tsunoka
    Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, 470 1192, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 33:875-9. 2009
    ..Therefore, we studied the association between Group II mGluR genes (GRM2 and GRM3) and mood disorders and the efficacy of fluvoxamine treatment in Japanese MDD patients.
  81. ncbi A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine
    K Ito
    Department of Psychiatry, Akita University School of Medicine, Akita, Japan
    Psychiatry Res 111:235-9. 2002
    ..whether the allelic variation of VNTR in the STin2 was associated with the antidepressant response to fluvoxamine in 66 patients with major depressive disorder...
  82. ncbi Repeated treatment with imipramine, fluvoxamine and tranylcypromine decreases the number of escape failures by activating dopaminergic systems in a rat learned helplessness test
    K Takamori
    CNS Diseases Research, Laboratory 1, Medicinal Research Laboratories, Taisho Pharmaceutical Co, Ltd, Ohmiya, Saitama, Japan
    Life Sci 69:1919-26. 2001
    ..o.), fluvoxamine (1.25 mg/kg, p.o.) and tranylcypromine (1.25 mg/kg, p.o...
  83. ncbi Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients
    Shingo Naito
    Department of Psychiatry, Akita University School of Medicine, Akita, Japan
    Psychiatry Clin Neurosci 61:421-7. 2007
    Gender differences in the treatment response to fluvoxamine (selective serotonin re-uptake inhibitor) and milnacipran (serotonin/norepinephrine re-uptake inhibitor) were investigated in Japanese major depressive patients...
  84. ncbi Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders
    Wayne L Strauss
    Center on Human Development and Disability, University of Washington, Seattle, 98105 6099, USA
    Am J Psychiatry 159:755-60. 2002
    ..The authors used fluorine magnetic resonance spectroscopy ((19)F MRS) to evaluate age effects on whole-brain concentrations of fluvoxamine and fluoxetine in children taking SSRIs.
  85. ncbi [Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods]
    Hisashi Higuchi
    Department of Neuropsychiatry, St Marianna Medical University School of Medicine, 2 16 1, Sugao, Miyamae ku, Kawasaki, 216 8511 Japan
    Nihon Shinkei Seishin Yakurigaku Zasshi 30:71-6. 2010
    ..In a fluvoxamine study, sixty-six patients with major depressive disorder were treated with fluvoxamine, 100-200 mg/day, for 6 ..
  86. ncbi High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503
    Masatomo Ishikawa
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan
    Biol Psychiatry 62:878-83. 2007
    ..Among the several SSRIs, fluvoxamine has the highest affinity for sigma-1 receptors (Ki = 36 nM), whereas paroxetine shows low affinity (Ki = 1893 ..
  87. ncbi Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserine
    V Manna
    Department of Mental Health, National Health Service, Troia, Foggia, Italy
    Headache 34:44-9. 1994
    ..baseline period, then they were randomized in double-blind fashion to therapy with mianserine (30-60 mg/day) of fluvoxamine (50-100 mg/day) for another eight-week period...
  88. ncbi Effects of fluvoxamine on anxiety, depression, and subjective handicaps of chronic dizziness patients with or without neuro-otologic diseases
    Arata Horii
    Department of Otolaryngology, Osaka University School of Medicine, Suita, Osaka, Japan
    J Vestib Res 17:1-8. 2007
    A prospective, open-label clinical trial was conducted for two aims: first, to evaluate the role of fluvoxamine, one of selective serotonin reuptake inhibitors, in the treatment of dizziness for the first time and to investigate its ..
  89. ncbi Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder
    Bernardo Dell'Osso
    Compulsive, Impulsive and Anxiety Disorders Program, Department of Psychiatry, Mount Sinai School of Medicine, Box 1230, New York, NY 10029, USA
    Expert Opin Pharmacother 6:2727-40. 2005
    b>Fluvoxamine is the selective serotonin re-uptake inhibitor with the largest database in the treatment of obsessive-compulsive disorder, a severe, and often chronic, anxiety disorder associated with substantial impairment in functioning...
  90. ncbi Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors
    Kenji Hashimoto
    Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan
    Neuropsychopharmacology 32:514-21. 2007
    This study was undertaken to examine the effects of the selective serotonin reuptake inhibitors fluvoxamine and paroxetine on cognitive deficits in mice after repeated administration of the N-methyl-D-aspartate receptor antagonist ..
  91. pmc Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine
    John S Mitcheson
    Department of Cell Physiology and Pharmacology, University of Leicester, Maurice Shock Medical Sciences Building, University Road, Leicester LEI 9HN
    Br J Pharmacol 139:883-4. 2003
  92. ncbi Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine
    F Benedetti
    Department of Clinical Neurosciences, Istituto Scientifico Ospedale San Raffaele, University Vita Salute San Raffaele, San Raffaele Turro, Via Stamira d Ancona 20, Milan, Italy
    Eur Psychiatry 25:476-8. 2010
    ..Recent clinical studies found a significant effect of rs4680 on antidepressant response to fluoxetine and paroxetine, but several other studies were negative. No study considered drug plasma levels as possible nuisance covariate...
  93. ncbi Gene expression changes in peripheral mononuclear cells from schizophrenic patients treated with a combination of antipsychotic with fluvoxamine
    Yael Chertkow
    Molecular Neuropsychiatry Unit, Shaar Menashe Brain Behavior Laboratory, Shaar Menashe MHC, and Technion Faculty of Medicine, Haifa, Israel
    Prog Neuropsychopharmacol Biol Psychiatry 31:1356-62. 2007
    ..Gene expression profile of PMC from antipsychotic-treated patients was examined before addition of the SSRI fluvoxamine, and 3 and 6 weeks after...
  94. ncbi Dose-dependent effects of the 3435 C>T genotype of ABCB1 gene on the steady-state plasma concentration of fluvoxamine in psychiatric patients
    Naoki Fukui
    Department of Psychiatry, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
    Ther Drug Monit 29:185-9. 2007
    This study investigated effects of the 3435 C>T genotype of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1, MDR1) gene on the steady-state plasma concentration of fluvoxamine (FLV).
  95. ncbi Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder
    A Palatnik
    Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheba, Israel
    J Clin Psychopharmacol 21:335-9. 2001
    ..controlled, random-order crossover study was undertaken to compare the effect of inositol with that of fluvoxamine in panic disorder...
  96. ncbi 24-Hour motor activity after treatment with imipramine or fluvoxamine in major depressive disorder
    Anita C Volkers
    Department of Psychiatry, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Eur Neuropsychopharmacol 12:273-8. 2002
    ..this study was to evaluate in 52 depressed in-patients the effects of imipramine (tricyclic antidepressant) and fluvoxamine (SSRI) on the 24-h motor activity...
  97. ncbi Oniomania--successful treatment with fluvoxamine and cognitive-behavioral psychotherapy
    Darko Marcinko
    University Psychiatric Clinic Rebro, Clinical Hospital Centre Zagreb Croatia
    Psychiatr Danub 17:97-100. 2005
    ..We have presented the case of a 32-year old woman with a history of excessive pathological buying treated successfully with combined therapy (fluvoxamine and cognitive-behavioral psychotherapy).
  98. ncbi Short-term single-blind fluvoxamine treatment of pathological gambling
    E Hollander
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 155:1781-3. 1998
    The authors' goal was to assess the efficacy and tolerability of the selective serotonin reuptake inhibitor fluvoxamine in the treatment of pathological gambling.
  99. pmc Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634]
    Pieter C J ter Borg
    Department of Gastroenterology and Hepatology, Erasmus MC, Dr, Molewaterplein 40, Rotterdam, The Netherlands
    BMC Gastroenterol 4:13. 2004
    ..symptom of depression and there is some evidence that treatment with an antidepressant improves fatigue in patients with fibromyalgia, we hypothesised that the antidepressant fluvoxamine might improve fatigue related to PBC and PSC.
  100. ncbi A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder
    Herman G M Westenberg
    Department of Biological Psychiatry, University Hospital Utrecht, The Netherlands
    J Clin Psychopharmacol 24:49-55. 2004
    ..double-blind placebo-controlled multicenter study to assess the efficacy, safety, and tolerability of fluvoxamine in a controlled release (CR) formulation for treatment of generalized social anxiety disorder (GSAD)...
  101. ncbi Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study
    Stefano Erzegovesi
    Department of Neurosciences, San Raffaele Hospital, Vita Salute San Raffaele University, Via Stamira d Ancona 20, 20127 Milan, Italy
    Eur Neuropsychopharmacol 15:69-74. 2005
    ..The aims of our study were to evaluate the efficacy of risperidone addition, in comparison to placebo, in fluvoxamine-refractory obsessive-compulsive patients and to investigate whether risperidone could boost the efficacy of ..

Research Grants62

  1. 5-HT transporter function: Interaction of hormones and antidepressants
    Alan Frazer; Fiscal Year: 2013
    ..are that acute treatment with either estradiol or progesterone will block the ability of locally applied fluvoxamine, an SSRI, either to elevate extracellular levels of serotonin in the hippocampus or its ability to decrease ..
  2. Organic Cation Transporters as Targets for Novel Antidepressant Drugs
    Wouter Koek; Fiscal Year: 2013
    ..For example, D-22 augments the effect of an SSRI, fluvoxamine, to inhibit 5-HT uptake and to produce antidepressant-like effects in wildtype mice...
  3. NEURONAL INTERACTIONS IN THE SRI TREATMENT OF PANIC
    Andrew Goddard; Fiscal Year: 2000
    ..alpha2 adrenergic antagonist yohimbine but no panic following a saline control, will be stabilized on the SRI, fluvoxamine. Patients that respond to fluvoxamine will then participate in two experimental tests, one involving a ..
  4. NEUROBIOLOGY AND TREATMENT OF OCD
    Wayne Goodman; Fiscal Year: 1999
    ..primarily on the anti-obsessive-compulsive (OC) efficacy of potent serotonin reuptake inhibitors (SRIs) such as fluvoxamine. Although SRIs are an advance in the treatment of OCD, many patients fail to respond and few become ..
  5. Bupropion VS Placebo to Treat Pathological Gambling
    Donald Black; Fiscal Year: 2004
    ..samples to help test whether specific subgroups will improve preferentially, and comparisons of bupropion with the SSRI fluvoxamine, and naltrexone, an opiate antagonist, both shown to have efficacy in treating PG.
  6. METABOLIC ASPECTS OF BODY WEIGHT CHANGE IN DEPRESSION
    Madelyn Fernstrom; Fiscal Year: 1991
    ..In depressed inpatients hospitalized for 4 weeks, the effects of two antidepressants (desipramine and fluvoxamine) on metabolic rate will be compared. Data will also be obtained on caloric intake in treated subjects...
  7. Adrenergic Receptors During Periadolescent Development
    David Bylund; Fiscal Year: 2005
    ..drugs that effect the noradrenergic and serotonin systems (the selective re-uptake inhibitors desipramine and fluvoxamine)...
  8. R21 Project: St. John's Wort vs. Placebo in OCD
    Kenneth Kobak; Fiscal Year: 2003
    ..g., drop-out rates in the multi-center trials of fluoxetine, fluvoxamine, sertraline, and paroxetine were 23%, 24%, 27%, and 20% respectively...
  9. BRAIN METABOLISM AND TREATMENT OUTCOME IN PANIC DISORDER
    Stephen Dager; Fiscal Year: 2004
    ..and then again at 12 weeks following randomization of the panic subjects into treatment with CBT (n=40) or fluvoxamine (n=40)...
  10. RUPP-PI at Duke
    Karen Wells; Fiscal Year: 2006
    ..Our work in the RUPP fluvoxamine anxiety trial suggests that partial responders to SSRI trials are not uncommon...
  11. SEROTONIN/NOREPINEPHRINE FUNCTION--PATHOLOGICAL GAMBLING
    Eric Hollander; Fiscal Year: 2000
    ..Our pharmacological treatment studies with the serotonin reuptake blocker fluvoxamine revealed a reduction in actual pathological gambling behavior...
  12. Opioid Dependence and Pathological Gambling
    Carlos Blanco; Fiscal Year: 2005
    ..dependent patients with and without pathological gambling and controls, and a randomized clinical trial of fluvoxamine combined with manual- guided cognitive-behavioral relapse-prevention therapy (CBT/RP) in methadone maintained ..
  13. The Social Neuroscience of Autism and Related Disorders
    Fred Volkmar; Fiscal Year: 2007
    ..in children and adolescents with PDD and to evaluate the effects of the selective serotonin reuptake inhibitor, fluvoxamine, in a randomized double-blind, placebo-controlled trial...
  14. AMPHETAMINE, INSULIN AND THE DA TRANSPORTER IN VIVO
    Lynette Daws; Fiscal Year: 2005
    ..In turn, these studies may help to illuminate the neural mechanisms underlying the high co-morbidity of eating disorders and drug abuse. ..
  15. Training in Psychopharmacology and Outcomes Research
    Eric Hollander; Fiscal Year: 2008
    ..of Medicine of Medicine of Medicine of Medicine of Medicine of Medicine format shown below. Role on ..
  16. Greater New York Autism Research Center of Excellence
    Joseph Buxbaum; Fiscal Year: 2007
    ..Core B: Clinical Core; Core C: Data Management and Statistics Core; Core D: Information Transfer Core. ..
  17. FLUOXETINE IN PEDIATRIC BODY DYSMORPHIC DISORDER
    Eric Hollander; Fiscal Year: 2008
    ..Abstract Not Provided. ..
  18. PHARMACOTHERAPY OF ADOLESCENT BODY DYSMORPHIC DISORDER
    Eric Hollander; Fiscal Year: 2002
    ..When untreated, adolescent-onset BDD appears to often interfere with the developmental tasks of adolescence, to persist, and to cause substantial morbidity through out the life span. ..
  19. Divalproex Sodium/Placebo In Child/Adolesent Autism
    Eric Hollander; Fiscal Year: 2003
    ....
  20. Age, ethanol, and strain effects on the behavioral pharmacology of cannabinoids
    BRETT GINSBURG; Fiscal Year: 2008
    ..This project will help us understand how aging, exposure to ethanol, and perhaps genetic disposition change the behavioral response to these drugs. [unreadable] [unreadable] [unreadable]..
  21. Models for examining selective effects of pharmacotherapy on reinforced behaviors
    BRETT GINSBURG; Fiscal Year: 2008
    ..This project will clarify important factors involved in studies of alcohol effects and potential medications for alcoholics. [unreadable] [unreadable] [unreadable]..
  22. PGP Regulation of Antipsychotic Exposure and Effects
    C Devane; Fiscal Year: 2008
    ..The results of this research will provide support for translational studies in humans to refine treatment guidelines for the use of this class of medications in severely mentally ill patients. ..
  23. Pharmacogenetics of Methadone
    C Devane; Fiscal Year: 2003
    ..This study will form the basis for subsequent studies which should provide a more rational basis for dosing of methadone in pregnant addicts. ..
  24. PULSE LOADED IV CLOMIPRAMINE IN UNRESPONSIVE OCD
    Lorrin Koran; Fiscal Year: 2001
    ..outcome can be predicted from baseline clinical information. (Throughout this revised grant application, revisions are indicated by bold type face, except that the new Introduction is in ordinary typeface). ..
  25. Carbohydrate Metabolism in Late Pregnancy
    Mary Moore; Fiscal Year: 2005
    ..Preliminary studies in the pregnant dog model in fact suggest that multiple counterregulatory mechanisms are altered by pregnancy. ..
  26. Emory Conte Center for the Neuroscience of Mental Disorders
    Becky Kinkead; Fiscal Year: 2008
    ..abstract_text> ..
  27. FLUOXETINE AND BEHAVIOR THERAPY IN SOCIAL PHOBIA
    Jonathan Davidson; Fiscal Year: 2001
    ..Effective treatments can be a long way towards reducing the societal burden associated with the disorder. ..
  28. Development and Applications of Novel SERT PET Ligands
    Mark Goodman; Fiscal Year: 2006
    ..Once SERT binding is determined in depressed patients, we will be able to assess the relationship of SERT binding and treatment response to SSRIs. ..
  29. Computerized Decision Support System for Depression
    Madhukar Trivedi; Fiscal Year: 2007
    ..Comparisons will be made between CDSS-D, PPA-D, and UC-D. [unreadable] [unreadable]..
  30. RESEARCH TRAINING IN CHILD PSYCHOPATHOLOGY & TREATMENT
    Mark Riddle; Fiscal Year: 2008
    ..This training program is thoughtfully organized to produce a cadre of graduates who will become productive independent interventions researchers in child and adolescent major mental disorders. ..
  31. CONTROLLED FAMILY STUDY IN PATIENTS WITH FIBROMYALGIA
    Lesley Arnold; Fiscal Year: 2001
    ..abstract_text> ..
  32. REVAMP Follow-Up
    Madhukar Trivedi; Fiscal Year: 2008
    ....
  33. INTEGRATIVE NEUROBIOLOGY OF ALCOHOL WITHDRAWAL SEIZURES
    Carl Faingold; Fiscal Year: 2002
    ..We expect these approaches to yield novel insights into the neurobiological mechanisms controlling seizure susceptibility during ethanol withdrawal and suggest improved approaches to the therapy of alcoholism. ..
  34. KAVA KAVA IN GENERALIZED ANXIETY: A DOUBLE-BLIND TRIAL
    Jonathan Davidson; Fiscal Year: 2001
    ..It will also contribute towards providing an answer to what is rapidly becoming a major public health question, namely what can we reasonably expect herbal treatments to offer? ..
  35. RUPP-PI in New York City
    Laurence Greenhill; Fiscal Year: 2006
    ..The expertise and experience at this RUPP-PI site also will be directed to train new investigators. In creating TASA, a collaborative group of 8 RUPP-PI applicants forged the ability to work together. ..
  36. CAREER DEVELOPMENT AWARD IN PEDIATRIC PSYCHOPHARMACOLOGY
    Andres Martin; Fiscal Year: 2004
    ..practical substrate for the training plan described: 1) A double-blind, placebo- controlled study of low-dose fluvoxamine in the treatment of obsessive, compulsive, and general anxiety symptoms in adolescents diagnosed with Asperger ..
  37. Use of Chronoamperometry to Measure Extracellular 5 HT
    Alan Frazer; Fiscal Year: 2005
    ..These experiments involve multiple approaches to study an effect of specific antidepressant drugs that may be very important in sustaining the enhancement of monoaminergic transmission that underlies clinical improvement ..
  38. Functional neuroanatomical deficits in ADHD families
    Laurence Greenhill; Fiscal Year: 2004
    ..Imaging will be performed at corresponding imaging sites at DUMC, Weill Medical College of Cornell University, and Stanford University respectively. ..
  39. Treatment with Exercise Augmentation for Depression
    Madhukar Trivedi; Fiscal Year: 2006
    ....
  40. IMPROVING CARE FOR PANIC DISORDER IN PRIMARY CARE
    Murray Stein; Fiscal Year: 2002
    ..abstract_text> ..
  41. OCD TREATMENT OUTCOMES--BEYOND PHASE 3 DRUG TRIALS
    Deborah Ackerman; Fiscal Year: 2002
    ..e., when people vary in their response to a particular treatment and in their risk for a given condition, and multiple- comparison artifacts that are frequently encountered in analyzing data from multicenter studies. ..
  42. Novel Pharmacological Strategies in Autism
    Christopher McDougle; Fiscal Year: 2009
    ..Phase II (following 6 months of aripiprazole monotherapy). ..
  43. South Texas Graduate Diversification Program
    Alan Frazer; Fiscal Year: 2006
    ..Talented URMs are available who are capable of having successful careers in mental health research. Our program is designed to recruit these students and demonstrate to them that the can be successful. ..
  44. Improving Outcomes in Pharmacotherapy of Social Phobia
    Michael Van Ameringen; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  45. Methodologic quality predictors of observational studies
    Nirav Shah; Fiscal Year: 2003
    ..Our research could identify potential deficiencies in the available data for a given area and guide future investigators on what common pitfalls to avoid when conducting original research in that field. ..
  46. Substance Use Comorbidity Care: Evidence-Based Stepped Strategies for Depression
    Carlos Blanco; Fiscal Year: 2010
    ..abstract_text> ..
  47. Molecular Analysis and Role of RGS6 as a Novel Growth Suppressor
    Rory A Fisher; Fiscal Year: 2010
    ..This work will determine how RGS6 works and will determine the basis for loss of RGS6 expression in human cancers. These studies could contribute to novel approaches in cancer therapy. ..
  48. SMART: Improving Detection & Outcome of Psychiatric Comorbidity in Drug Treatment
    Carlos Blanco; Fiscal Year: 2010
    ..abstract_text> ..
  49. Depression Prevention in Pregnant AI Teens Using CBT
    Golda Ginsburg; Fiscal Year: 2006
    ..If findings from the present study are positive, the intervention will be evaluated in a larger study (R01). ..
  50. Arterial 5-HT Transporter Function
    Stephanie Watts; Fiscal Year: 2009
    ..abstract_text> ..
  51. Screening for comorbidity in substance abuse clinics
    Carlos Blanco; Fiscal Year: 2004
    ..abstract_text> ..
  52. Stress and Marijuana Cue-Elicited Craving and Reactivity
    Aimee McRae; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  53. S-Adenosyl Methionine(SAMe)Augmentation of SSRIs in MDD
    George Papakostas; Fiscal Year: 2008
    ..It is hoped that this project award will provide the critical fund of basic knowledge and practical experience necessary to aid the candidate in becoming an independent investigator in this area. ..
  54. RGS6 Signaling and Function in Neural Development
    Rory Fisher; Fiscal Year: 2006
    ..abstract_text> ..
  55. Family Based Prevention for Childhood Anxiety
    Golda Ginsburg; Fiscal Year: 2006
    ..The specific aim of Study 2 is to conduct a controlled pilot evaluation of a family-based prevention intervention for reducing current levels of anxiety and preventing the onset of anxiety disorders in the offspring of anxious parents. ..
  56. Career Training in Marijuana Dependence
    Aimee McRae; Fiscal Year: 2006
    ..The primary outcome measure will be marijuana use as assessed by self-report and weekly urine drug screens. The results of this study will help guide future directions for research in the area of marijuana dependence. ..
  57. Atomoxetine Treatment for ADHD and Marijuana Dependence
    Aimee McRae Clark; Fiscal Year: 2006
    ..The project is designed to increase our knowledge of treatment options for patients with marijuana dependence, an area which has been under investigated. [unreadable] [unreadable]..
  58. Preventing Psychiatric Sequelae of Traumatic Injury
    Murray Stein; Fiscal Year: 2003
    ..Findings will provide justification for and information about optimal parameters (e.g., subject selection; sample size; dose and duration) for a future randomized controlled trial (RCT). ..
  59. RUPP-PI
    Christopher McDougle; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable] [unreadable] ..
  60. Follow-up of the PATS Sample
    Mark Riddle; Fiscal Year: 2008
    ..Aim 4 is to determine the stability of the ADHD diagnosis and other comorbidities made for study entry at age 3-5 years across subsequent development [unreadable] [unreadable]..
  61. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael E Thase; Fiscal Year: 2010
    ....